CSPC Pharmaceutical Focus on the Ascending Triangle

CSPC Pharmaceutical (1093.HK): Focus on the Ascending Triangle

CSPC Pharmaceutical (1093), a drug maker, announced that 1Q net income rose 21.8% on year to 1.16 billion yuan and operating profit grew 0.6% to 1.16 billion yuan on revenue of 6.13 billion yuan, up 11.5%.

After the announcement of 1Q result, the stock jumped 6%. However, the stock failed to close above the April high at HK$17.20. Currently, the stock eased around 3%.

Source: GAIN Capital, TradingView

On a daily chart, the stock remains trading within the ascending triangle. A upside breakout could mean the bullish reversal signal. Otherwise, A break below the rising trend line could signal a continuation of the previous down trend.

In fact, both 20-day and 50-day moving averages are flattening. The RSI is capped by a resistance level at 59, but supported by a rising trend line at same time. Both indicators would suggest the lack of momentum for the prices.

In this case, the reader should consider a neutral bias and focus on the breakout signal in the future.

A clear break above HK$17.20 (the high of April) could consider a rise to the next resistance level at HK$19.26 (the high of March.

In an alternative scenario, crossing below HK$15.00 (the previous low) might bring a return to $13.12 (the low of March).

From time to time, StoneX Financial Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.

City Index is a trading name of StoneX Financial Pty Ltd.

The material provided herein is general in nature and does not take into account your objectives, financial situation or needs.

While every care has been taken in preparing this material, we do not provide any representation or warranty (express or implied) with respect to its completeness or accuracy. This is not an invitation or an offer to invest nor is it a recommendation to buy or sell investments.

StoneX recommends you to seek independent financial and legal advice before making any financial investment decision. Trading CFDs and FX on margin carries a higher level of risk, and may not be suitable for all investors. The possibility exists that you could lose more than your initial investment further CFD investors do not own or have any rights to the underlying assets.

It is important you consider our Financial Services Guide and Product Disclosure Statement (PDS) available at www.cityindex.com/en-au/terms-and-policies/, before deciding to acquire or hold our products. As a part of our market risk management, we may take the opposite side of your trade. Our Target Market Determination (TMD) is also available at www.cityindex.com/en-au/terms-and-policies/.

StoneX Financial Pty Ltd, Suite 28.01, 264 George Street, Sydney, NSW 2000 (ACN 141 774 727, AFSL 345646) is the CFD issuer and our products are traded off exchange.